Lisinopril
Based on 6 publication(s) in Google Scholar
Lisinopril (MK-521) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.98%
- No. CAS: 76547-98-3
- Fòrmula: C21H31N3O5
- Peso molecular:405.49
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Metabolism/Protease Compound Library
HY-L012
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Anti-diabetic Compound Library
HY-L040
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Angiogenesis-Related Compound Library
HY-L088
-
Rare Diseases Drug Library
HY-L102
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Antihypertensive Compound Library
HY-L145
-
Protease Inhibitor Library
HY-L147
-
Membrane Protein-targeted Compound Library
HY-L149
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Nephrotoxicity Compound Library
HY-L229
-
Natural Product Diversity Scaffold Library
HY-L245
-
RNA Binding Bioactive Compound Library
HY-L248
Publications Citing Use of MedChemExpress (MCE) Lisinopril
More- Nat Commun. 2023 Sep 21;14(1):5891. [Abstract]
- J Pharm Anal. 2025 Aug;15(8):101265. [Abstract]
- Commun Biol. 2026 Mar 31;9(1):705. [Abstract]
- Biomedicines. 2022 Jul 11;10(7):1661. [Abstract]
- Am J Physiol Renal Physiol. 2021 Aug 1;321(2):F149-F161. [Abstract]
- Hum Cell. 2020 Apr;33(2):330-336. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
WB
Actividad biológica
ACE.
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
307 μM
Compound: Lisinopril
|
Cytotoxicity against human A549 cells assessed as cell survival after 24 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell survival after 24 hrs by MTT assay
|
[PMID: 23777825] |
| HEK293 | IC50 |
443 μM
Compound: Lisinopril
|
Cytotoxicity against HEK293 cells assessed as cell survival after 24 hrs by MTT assay
Cytotoxicity against HEK293 cells assessed as cell survival after 24 hrs by MTT assay
|
[PMID: 23777825] |
Lisinopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Lisinopril may be used to treat hypertension and symptomatic congestive heart failure, to improve survival in certain individuals following myocardial infarction, and to prevent progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 76547-98-3
-
Appearance Solid
-
Peso molecular 405.49
-
Fòrmula C21H31N3O5
-
Color White to off-white
-
SMILES
O=C(O)[C@H]1N(C([C@H](CCCCN)N[C@H](C(O)=O)CCC2=CC=CC=C2)=O)CCC1
-
Synonyms
MK-521
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Endothelial Sp1/Sp3 are essential to the effect of captopril on blood pressure in male mice. [Abstract]2023 Sep 21;14(1):5891. PMID: 37735515 -
J Pharm Anal
Prioritization of potential drug targets for diabetic kidney disease using integrative omics data mining and causal inference. [Abstract]2025 Aug;15(8):101265. PMID: 40979545 -
Commun Biol
2026 Mar 31;9(1):705. PMID: 41917198 -
Biomedicines
Nephroprotective Effects of Semaglutide as Mono- and Combination Treatment with Lisinopril in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease. [Abstract]2022 Jul 11;10(7):1661. PMID: 35884965 -
Am J Physiol Renal Physiol
Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease. [Abstract]2021 Aug 1;321(2):F149-F161. PMID: 34180715 -
Hum Cell
Silibinin enhances anti-renal fibrosis effect of MK-521 via downregulation of TGF-β signaling pathway. [Abstract]2020 Apr;33(2):330-336. PMID: 31953678
Lisinopril purchased from MedChemExpress. Usage Cited in: Hum Cell. 2020 Apr;33(2):330-336. [Abstract]
HK-2 cells are treated with 0, 5, 10, 20 and 40 μM MK-521 for 48 h, and cell viability was determined by CCK-8 assay. HK-2 cells are treated with 40 μM silibinin or/and 10 μM MK-521 for 48 h, and cell viability was determined by CCK-8 assay.
Lisinopril purchased from MedChemExpress. Usage Cited in: Hum Cell. 2020 Apr;33(2):330-336. [Abstract]
After 72 h of incubation, the protein expressions of collagen I, MMP9, α-SMA, smad2, smad3, p-smad2 and p-smad3 in control, TGF-β1 (5 ng/ml), MK-521 (10 μM), TGF-β1+MK-521, silibinin (40 μM) and TGF-β1+MK-521+silibinin are detected by Western blot. GAPDH was used as a loading control.
Solvente y solubilidad
H2O : 50 mg/mL (123.31 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (277 KB)
-
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Andujar-Sanchez, M., V. Jara-Perez, and A. Camara-Artigas, Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method. FEBS Lett, 2007. 581(18): p. 3449-54. [Content Brief]
[2]. Song, J.C. and C.M. White, Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet, 2002. 41(3): p. 207-24. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 2.4662 mL | 12.3308 mL | 24.6615 mL | 61.6538 mL |
| 5 mM | 0.4932 mL | 2.4662 mL | 4.9323 mL | 12.3308 mL | |
| 10 mM | 0.2466 mL | 1.2331 mL | 2.4662 mL | 6.1654 mL | |
| 15 mM | 0.1644 mL | 0.8221 mL | 1.6441 mL | 4.1103 mL | |
| 20 mM | 0.1233 mL | 0.6165 mL | 1.2331 mL | 3.0827 mL | |
| 25 mM | 0.0986 mL | 0.4932 mL | 0.9865 mL | 2.4662 mL | |
| 30 mM | 0.0822 mL | 0.4110 mL | 0.8221 mL | 2.0551 mL | |
| 40 mM | 0.0617 mL | 0.3083 mL | 0.6165 mL | 1.5413 mL | |
| 50 mM | 0.0493 mL | 0.2466 mL | 0.4932 mL | 1.2331 mL | |
| 60 mM | 0.0411 mL | 0.2055 mL | 0.4110 mL | 1.0276 mL | |
| 80 mM | 0.0308 mL | 0.1541 mL | 0.3083 mL | 0.7707 mL | |
| 100 mM | 0.0247 mL | 0.1233 mL | 0.2466 mL | 0.6165 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Lisinopril Related Classifications
HY-18206 Related Classifications
Powered by Bioz